ArticleBMC ophthalmology2018

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.

Patrick R Merz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.